Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere (Docetaxel) Plus Vectibix (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study.
Phase of Trial: Phase II
Latest Information Update: 13 May 2014
At a glance
- Drugs Panitumumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms TVA
- 14 Dec 2013 Results presented at the 36th Annual San Antonio Breast Cancer Symposium.
- 28 Jun 2012 Companies added in the association field as reported by EudraCT.
- 18 Jan 2012 Actual patient number (62) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History